HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- O- (4- O- galactopyranosyl- glucopyranosyl)- 1,2- di- O- tetradecyl- sn- glyceryol

RN & structure given in first source

Also Known As:

DTLL

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycolipids: 2799
    - Galactolipids: 66
      - 3-O-(4-O-galactopyranosyl-glucopyranosyl)-1,2-di-O-tetradecyl-sn-glyceryol: 2
Lipids: 114793
- Glycolipids: 2799
  - Galactolipids: 66
    - 3-O-(4-O-galactopyranosyl-glucopyranosyl)-1,2-di-O-tetradecyl-sn-glyceryol: 2

Experts

1.	Cao, Rui: 1 article (01/2019)
2.	Li, Liang: 1 article (01/2019)
3.	Li, Yi: 1 article (01/2019)
4.	Liu, Xiujun: 1 article (01/2019)
5.	Shao, Rongguang: 1 article (01/2019)
6.	Song, Wenping: 1 article (01/2019)
7.	Yao, Hongjuan: 1 article (01/2019)
8.	Ye, Cheng: 1 article (01/2019)
9.	Zhou, Xiaofei: 1 article (01/2019)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2019 - "Our studies on DTLL functional characterization revealed its novel mechanisms on internal enhancement of DNA damage and implied that DTLL might provide a promising targeted therapeutic strategy for pancreatic cancer." 01/01/2019 - "It suggested that DTLL might be a highly potent bispecific antibody-drug conjugate (ADC)-like agent for pancreatic cancer therapy. " 01/01/2019 - "We generated a dual-targeting ligand-based lidamycin (DTLL) to investigate its efficacy against pancreatic cancer after preparing its precursor, DTLP. "
2.	Neoplasms (Cancer) 01/01/2019 - "The results from both in vitro and in vivo experiments suggested that DTLL enhanced DNA damage via EGFR/HER2-dependent blockage of PI3K/AKT/mTOR and PD-L1 signaling pathways in cancer cells, leading to the inhibition of cell proliferation and immunosurveillance escape from pancreatic tumor. " 01/01/2019 - "Pancreatic tumors of either MIA-paca-2 cell line-derived (CDX) or patient-derived xenograft (PDX) mouse models were significantly regressed in response to DTLL. " 01/01/2022 - "DTLL in combination with gemcitabine show a superior inhibitory effect on the growth of gemcitabine-resistant/sensitive tumors. " 01/01/2019 - "LDM is known to function as an antitumor cytotoxic agent by its induction of DNA damage in cancer cells, therefore, DTLL, as its derivative, also showed similar cytotoxicity. "

Related Drugs and Biologics

1.	Ligands
2.	C 1027
3.	Immunoconjugates (Immunoconjugate)
4.	Cytotoxins (Cytolysins)
5.	Gemcitabine

Related Therapies and Procedures

1.	Therapeutics